2023
DOI: 10.1016/j.ijrobp.2022.09.072
|View full text |Cite
|
Sign up to set email alerts
|

GEC-ESTRO (ACROP)–ABS–CBG Consensus Brachytherapy Target Definition Guidelines for Recurrent Endometrial and Cervical Tumors in the Vagina

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
14
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 15 publications
(14 citation statements)
references
References 30 publications
0
14
0
Order By: Relevance
“…Target definition of brachytherapy for vaginal cancer had always been a focus, and in October 2022, brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina were published [ 22 ]. The guidelines provided definitions and comments on gross tumor volume (GTV) res , clinical target volume (CTV)-T HR , and CTV-T IR .…”
Section: Discussionmentioning
confidence: 99%
“…Target definition of brachytherapy for vaginal cancer had always been a focus, and in October 2022, brachytherapy target definition guidelines for recurrent endometrial and cervical tumors in the vagina were published [ 22 ]. The guidelines provided definitions and comments on gross tumor volume (GTV) res , clinical target volume (CTV)-T HR , and CTV-T IR .…”
Section: Discussionmentioning
confidence: 99%
“…Achieving good implant geometry is crucial in all BT applications, as no optimisation process can correct for a poor implant. Poor implant geometry or inadequate applicator choice can compromise the dose to the target volume and OARs and negatively impact local control, acute and late toxicity [ 2 , 12 ]. In two prospective trials, patients whose implant was classified as inadequate had a higher risk of local failure compared to those treated with an adequate implant (HR = 2.5, p = 0.04).…”
Section: The Rationale For Development Of 3d-printed Applicatorsmentioning
confidence: 99%
“…Gynaecological cancers represent an important health care burden, with cervical and endometrial cancer being the fourth and sixth most common cancers in women worldwide, respectively, and together account for more than 10% of all newly diagnosed cancers in women in 2020 [ 1 ]. Radiotherapy, including image-guided adaptive brachytherapy (IGABT) based on magnetic resonance (MR), is the standard of care in locally advanced cervical and vaginal cancer and also an integral part of curative treatment of (medically) inoperable endometrial cancer, locally recurrent cervical and endometrial cancer [ 2 , 3 , 4 ].…”
Section: Introductionmentioning
confidence: 99%
“…Vaginal recurrences from gynecological malignancies pose clinical challenges. Organ-preserving approaches with EBRT and IGBT play an important roles in the treatment of vaginal recurrence from endometrial cancer and cervical cancer [ 10 13 ]. It has been shown that brachytherapy (BT) can improve survival and is an important component of definitive radiotherapy in vaginal cancer [ 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%